Zimmer Biomet reports 4.8% YoY revenue uptick in Q2; raises 2026 outlook
Zimmer Biomet reported Q2 revenue of about $2.18bn, up 4.8% YoY. Knees led at $828.9m, followed by S.E.T. at $586m and hips at $562.7m. The company raised its 2026 revenue growth outlook to 3.9% to 4.9% and adjusted EPS to $8.47 to $8.59 per diluted share. Shares rose over 5% to about $101 at the open.
How this was made
The 30-second read
Why it matters
The company’s Q2 revenue uptick and raised 2026 revenue and EPS ranges create a fresh valuation catalyst, while segment performance details highlight where growth is accelerating versus where it is flat.
Market read
A guidance raise with specific 2026 ranges is a direct re-pricing input for ZBH and a sentiment read-through for orthopedics medtech execution.
What to watch
Traders may be underweighting segment-level profit dynamics: the article notes the lowest-profit segment in Q2 (technology and data, bone cement and surgical) even as it shows the highest YoY growth, which can mask margin sustainability.
Background
Zimmer Biomet previously tempered its 2026 outlook due to planned investment in a stronger, specialized US sales force, discussed at the J.P. Morgan Healthcare conference in January.
Ticker impact
Zimmer Biomet raised 2026 revenue growth to 3.9% to 4.9% and EPS to $8.47 to $8.59 after reporting Q2 revenue of about $2.18B.
Likely continued positive momentum versus peers into the next earnings cycle, with volatility around any follow-up commentary on US sales-force investment and product adoption.
The article provides specific, time-sensitive guidance ranges and ties them to go-to-market progress and innovation momentum, which typically drives re-rating in medtech.
Market effects
Signals improving demand and execution in orthopedics/implants, potentially supportive for medtech sentiment around elective procedure recovery and product adoption cycles.
US go-to-market changes are explicitly cited, which can influence expectations for domestic medtech sales execution.
International growth and new product adoption are referenced as drivers, implying broader execution beyond the US.
Counterpoint
The guidance raise may reflect mix and timing rather than durable demand, so upside could fade if knees growth remains weak (0.4% YoY) or if margins in the technology/data and bone cement segment stay pressured.
Key entities
- companyZimmer Biomet
Orthopedics medtech company reporting Q2 results and raising 2026 revenue and EPS guidance.
- personIvan Tornos
Zimmer Biomet CEO quoted on the drivers behind the revised outlook and prior guidance tempering.
